
RADNOR, Pa.--(BUSINESS WIRE)--PolyMedix, Inc. (OTC BB: PYMX, http://polymedix.com), an emerging biotechnology company developing acute care therapeutic drug products for infectious diseases and cardiovascular disorders, announced that data will be presented on its heptagonist compounds at the annual meeting of the American Society of Hematology in New Orleans, Louisiana.